Isofol Medical AB (5IU) Price & Analysis

Compare

1 Followers

5IU Stock Chart & Stats

€0.05

€0.01(5.26%)

At close: Jan 08 4:00 PM EST

€0.05

€0.01(5.26%)

Day’s Range― - ―

52-Week Range€0.04 - €0.16

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€16.35M

Enterprise Value€135.53M

Total Cash (Recent Filing)€126.99M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.45

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding281,107,240

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.39

Price to Book (P/B)1.46

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageZero reported debt across 2023–2025 materially reduces financial risk and interest burden. This gives management flexibility to allocate capital toward clinical programs and partnering without servicing debt, preserving strategic optionality over the next several months despite ongoing cash consumption.

Improved Cash BurnOperating outflows have fallen markedly from the extreme levels seen in 2020–2022, reflecting tighter cost control and a more sustainable spending profile. Sustained lower burn lengthens the effective runway per capital raise and improves the odds of reaching clinical/regulatory inflection points before further financing is required.

Focused Lead Asset & StrategyA single, well-defined lead candidate (arfolitixorin) and a strategy centered on development and partnering concentrate resources on proving efficacy and securing collaborators. This focused biotech model can unlock material value via trial and regulatory milestones and is attractive to potential partners.

Bears Say

No Revenue / Pre-commercial StatusThe absence of product revenue since 2024 leaves the company entirely pre-commercial, meaning operational funding depends on external capital or licensing. This structural lack of sales increases financing risk and limits internal ability to fund late‑stage trials or scale development without dilutive or conditional funding.

Equity Erosion From LossesMaterial reduction in shareholders' equity over multiple years reflects accumulated losses and capital dynamics, shrinking the balance sheet cushion. A smaller equity base constrains flexibility to pursue multiple programs, raises the likelihood of future dilutive financings, and weakens resilience to trial setbacks.

Negative Operating Cash FlowPersistently negative operating cash flow, even after improvement, indicates the company continues to consume significant cash to fund R&D and operations. Continued cash deficits imply ongoing reliance on capital markets or partners, which can delay programs or impose unfavorable terms if market conditions change.

Isofol Medical AB News

Isofol Extends Arfolitixorin Rights Into Autism While Keeping Cancer Focus

Isofol Medical AB ( ($SE:ISOFOL) ) has shared an update. Isofol Medical has expanded its global exclusive license...

6d ago

Isofol Sets TO1 Warrant Price and Exercise Window, Targets SEK 19 Million Raise

Isofol Medical AB ( ($SE:ISOFOL) ) has issued an update. Isofol Medical has set the subscription price for...

11d ago

Isofol Secures Stakeholder Support Covering 42% of Upcoming TO1 Warrant Exercise

The latest update is out from Isofol Medical AB ( ($SE:ISOFOL) ). Isofol Medical has secured a top...

13d ago

Isofol to Add Major Shareholder Christian Haglund to Expanded Board

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol’s nomination committee has proposed the...

15d ago

Isofol to Showcase Cancer Drug Candidate at Key March Investor Events

Isofol Medical AB ( ($SE:ISOFOL) ) has shared an announcement. Isofol Medical AB, listed on Nasdaq Stockholm, develops...

21d ago

Isofol Reports Strong Early Data for Arfolitixorin in Difficult-to-Treat Colorectal Cancer

The latest update is out from Isofol Medical AB ( ($SE:ISOFOL) ). Isofol Medical has reported encouraging interim...

28d ago

Isofol strengthens arfolitixorin program with new EU patent and advancing trials

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB continued development of...

1M ago

Isofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances

Isofol Medical AB ( ($SE:ISOFOL) ) has issued an announcement. Isofol Medical AB will participate in the ASCO...

2M ago

Isofol Medical to Showcase Arfolitixorin at Upcoming Investor Meetings

An update from Isofol Medical AB ( ($SE:ISOFOL) ) is now available. Isofol Medical AB announced its participation...

4M ago

Isofol Medical Secures New Patent for Cancer Drug Candidate Arfolitixorin

Isofol Medical AB ( ($SE:ISOFOL) ) just unveiled an update. Isofol Medical AB announced that the European Patent...

4M ago

5IU FAQ

What was Isofol Medical AB’s price range in the past 12 months?

Isofol Medical AB lowest stock price was €0.04 and its highest was €0.16 in the past 12 months.

What is Isofol Medical AB’s market cap?

Isofol Medical AB’s market cap is €16.35M.

When is Isofol Medical AB’s upcoming earnings report date?

Isofol Medical AB’s upcoming earnings report date is May 19, 2026 which is in 56 days.

How were Isofol Medical AB’s earnings last quarter?

Isofol Medical AB released its earnings results on Feb 18, 2026. The company reported -€0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.005.

Is Isofol Medical AB overvalued?

According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Isofol Medical AB pay dividends?

Isofol Medical AB does not currently pay dividends.

What is Isofol Medical AB’s EPS estimate?

Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Isofol Medical AB have?

Isofol Medical AB has 281,107,240 shares outstanding.

What happened to Isofol Medical AB’s price movement after its last earnings report?

Isofol Medical AB reported an EPS of -€0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.326%.

Which hedge fund is a major shareholder of Isofol Medical AB?

Currently, no hedge funds are holding shares in DE:5IU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Isofol Medical AB

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. It has strategic collaborations with Recipharm, Merck & Cie, and Sahlgrenska University Hospital. The company was incorporated in 2008 and is headquartered in Gothenburg, Sweden.